One significant barrier to better understanding the growing dilemma of chronic cancer pain is the lack of consistent diagnostic criteria that can be used in research and clinical settings. A common taxonomy would provide a foundation for studies of the prevalence, as well as the consequences of these pain syndromes for people with cancer, present evidence for the significance of this problem, support the need for improvements in management, and increase research efforts.^[@R153]^ This standardized classification system would enhance research efforts by ensuring greater homogeneity in pain conditions across clinical trials and support the development of animal models to replicate these cancer pain conditions. Ultimately, valid and reliable diagnostic criteria would facilitate clinical assessment and management and potentially guide prognostic accuracy.^[@R59],[@R65]^

Current systems to classify cancer pain provide general clinical utility. Cancer pain is often organized by its intensity (eg, mild, moderate, or severe), its expected time course (eg, acute vs chronic), its presumed underlying pathophysiology (eg, nociceptive vs neuropathic), its location (eg, head and neck pain), or its putative mechanisms (eg, tumor-related, treatment-related, pain unrelated to tumor or treatment).^[@R126]^ Although these general categories are useful, more specific diagnostic criteria would allow more precise diagnosis with therapeutic implications and would enhance research efforts.

This lack of a unified taxonomy is not specific to cancer pain. Currently, there is an absence of evidence-based classification systems for most chronic pain conditions.^[@R65]^ To meet this need, the Analgesic, Anesthetic, and Addiction Clinical Trial Translations Innovations Opportunities and Networks, a public-private partnership with the US Food and Drug Administration and the American Pain Society collaborated to develop the ACTTION-APS Pain Taxonomy (AAPT). The initiative worked to develop the characteristics of an ideal diagnostic system that would be biologically plausible, exhaustive, mutually exclusive, reliable, clinically useful, and simple through consensus conferences. The resulting diagnostic system includes 5 dimensions: 1) core diagnostic criteria; 2) common features; 3) common medical comorbidities; 4) neurobiological, psychological, and functional consequences; and 5) putative neurobiological and psychosocial mechanisms, risk factors, and protective factors.^[@R65]^

After the establishment of these 5 dimensions, a working subgroup of clinical and basic scientists and clinicians with expertise in cancer pain was convened by the AAPT organizers. The aim of their effort was to apply the ideal framework of 5 dimensions developed during the original AAPT conference to cancer pain. The objectives included: 1) to identify chronic pain syndromes seen in oncology with high prevalence and significant effects; and 2) to generate a classification system of diagnostic criteria for several of these syndromes on the basis of these originally proposed 5 dimensions.

Methods {#S1}
=======

A working group of clinicians and clinical and basic scientists with expertise in cancer pain met during a consensus meeting held in July 2014. Group members from the United States and the United Kingdom were carefully selected on the basis of their contributions to the science and management of cancer pain, representing multiple disciplines (basic scientists, physicians, and nurses) with significant achievements in cancer-related epidemiology, research, and clinical care.

Before this meeting, a systematic review was conducted by 2 of the working group members (M.M., M.B.) using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting system.^[@R99]^ The Preferred Reporting Items for Systematic Reviews and Meta-Analyses is an evidence-based minimum set of items for reporting systematic reviews and meta-analyses. The databases searched included the following: the Cumulative Index to Nursing and Allied Health Literature from 1981 to June 2014, the Cochrane Library of Systematic Reviews and the Cochrane Library of Controlled Trials from inception to June 2014, Database of Abstracts of Reviews of Effect from inception to April 2014, Embase Classic and Embase from 1947 to June 2014, Ovid MEDLINE 1946 to June 2014, and OVID MEDLINE In-Process and Other Non-Indexed Citations on June 11, 2014. These databases were searched for review articles (including summary reports, systematic reviews, and meta-analyses), as well as observational and experimental studies published in English. Articles were excluded if they did not describe the clinical characteristics of chronic cancer pain, including those that described animal studies, or were studies of acute or breakthrough cancer pain. Data were extracted and summarized descriptively with respect to the 5 AAPT diagnostic dimensions: 1) core diagnostic criteria; 2) common features; 3) common medical comorbidities; 4) neurobiological, psychosocial, and functional consequences; and 5) putative neurobiological and psychosocial mechanisms, risk factors, and protective factors. [Figure 1](#F1){ref-type="fig"} shows the process used in this systematic review. Key words included cancer pain, malignancy, chemotherapy, surgery, radiotherapy, and neuropathy.

Bone pain, postmastectomy pain, head and neck pain, neuropathic pain (disease-related), and chemotherapy-induced peripheral neuropathy (CIPN) were most frequently referenced. These results were correlated with prevalence data of pain reported according to tumor site, that generally show a higher rates of pain reports in people with pancreatic, lung, genitourinary, breast, and prostate cancers.^[@R20]^ The expert panel considered these and other pain syndromes aiming to initiate the process of taxonomy development with 3 syndromes before extending to the full range of cancer-related pain syndromes at a later time. The challenge in narrowing the selection to 3 syndromes was to achieve a balance between the most prevalent cancer pain syndromes versus areas that have received the most study and thus have the largest body of evidence. Ultimately guiding the selection was the aim to identify syndromes with clinical or research utility (ie, the painful conditions that are most homogeneous in terms of mechanism or presentation and offer the most relevant targets for further research).

Through working group discussion, debate, and verbal consensus, 3 chronic pain syndromes seen as a result of cancer (ie, bone pain and pancreatic cancer pain (PCP) as a model of pain related to the tumor) or its treatment (CIPN) were unanimously selected. Head and neck pain was omitted because the source of this pain may be multifactorial (eg, tumor, treatment-related, or both) and diverse in relationship to specific anatomic location. Similarly, the working group agreed that disease-related neuropathic pain was too broad. Although postsurgical pain syndromes, including postmastectomy pain, were initially included, this group of pain conditions was omitted from the cancer-related pain taxonomy to avoid overlap with a broader discussion of postsurgical pain syndromes being conducted concurrently by a separate working group classifying neuropathic pain.

Then the cancer pain working group generated a classification for these syndromes on the basis of the AAPT multidimensional framework. This work was conducted during the consensus meeting and later refined through online discussion. To ensure that the references were timely, the entire literature review was updated as of January 2015. The report on these findings was written by several members (J.A.P., M.M., M.B.) and reviewed, edited, and approved by all members of the working group.

Results {#S2}
=======

On the basis of this qualitative review and after extensive discussion, the diagnostic criteria for 3 representative chronic cancer-related pain syndromes were developed collectively by the working group, including cancer-induced bone pain (CIBP), CIPN, and PCP.

Cancer-Induced Bone Pain {#S3}
------------------------

It is estimated that 50 to 95% of all patients who die of cancer have bone involvement.^[@R49],[@R132]^ The most common cancers to originate in the bone are osteosarcomas.^[@R84]^ Cancers that frequently metastasize to bone include prostate, breast, lung, and myeloma.^[@R6],[@R7],[@R14],[@R29],[@R38],[@R42],[@R47],[@R50],[@R52],[@R75],[@R87],[@R94],[@R106],[@R136]^ Of those with bone metastases, approximately 85% experience pain, with resultant immobility and reduced quality of life.^[@R54]^ CIBP is a specific pain state with overlapping but distinct features of acute nociceptive, inflammatory, and neuropathic pain processes.^[@R61]^

### Dimension 1. Core Diagnostic Criteria of CIBP {#S4}

The AAPT core diagnostic criteria for CIBP are summarized in [Table 1](#T1){ref-type="table"}. The history must include a cancer diagnosis and imaging evidence of bone disease consistent with primary or metastatic cancer.

### Dimension 2. Common Features of CIBP {#S5}

The cardinal feature of CIBP is a mixture of continuous background pain (usually described as annoying, dull, gnawing, aching, and/or nagging) punctuated by evoked or spontaneous pain (often described as electric or shock-like) in 1 or more locations generally consistent with the given known distribution of bone lesions, associated with weight-bearing or movement or can occur spontaneously.^[@R14],[@R22],[@R40],[@R43],[@R48],[@R61],[@R63],[@R72],[@R73],[@R85],[@R88],[@R92],[@R95],[@R113],[@R123],[@R125],[@R130],[@R132],[@R133],[@R140]^ Generalized bone pain can occur because of the presence of multiple bone lesions or resultant expansion of bone marrow from bone metastases.^[@R26],[@R61]^ The distribution of the pain can be localized, radicular, or both.^[@R73]^

Typical sites of CIBP include the vertebrae (lower thoracic spine and lumbar regions are most prevalent), pelvis, long bones, and ribs.^[@R26],[@R48]^ Bone lesions on the skull can result in headache pain due to calvarial, maxillary, or medullary lesions, as well as cranial nerve palsies such as mental nerve numbness or visual difficulties.^[@R25],[@R26]^ Chest wall pain can occur as a result of bone lesions in the ribs.^[@R26]^

As the disease and tumor mass progress, the background pain increases in intensity and interference^[@R61]^ and is generally responsive to opioid analgesics, alone or in conjunction with nonsteroidal anti-inflammatory drugs.^[@R10],[@R22],[@R63],[@R71],[@R79],[@R112]^ Conversely, spontaneous pain (without specific eliciting stimuli) and evoked pain (ie, in response to standing, weight-bearing, movement, touch, or other stimuli) associated with CIBP are difficult to treat from the onset because of their intermittent nature, which tends to be very rapid in onset, intense, and of short duration.^[@R10],[@R22],[@R63],[@R71],[@R79],[@R112]^ Terminology commonly used in the clinical setting to describe evoked or spontaneous pain include breakthrough pain, incident pain, or a pain flare; however, definitions for these terms often lack precision and may overlap. For example, breakthrough pain is defined as a transitory flare of pain in the setting of chronic pain managed with opioid drugs,^[@R127]^ yet the evoked pain seen in CIBP can occur during weight-bearing without current opioid use. The International Association for the Study of Pain Taxonomy, the principal resource for definitions related to chronic pain, does not currently address evoked, breakthrough, incident, flare, or spontaneous pain.

### Dimension 3. Common Medical Comorbidities for CIBP {#S6}

The primary comorbidity for CIBP is the presence of skeletal-related events. These skeletal complications include pathological fractures of long bones, vertebrae, pelvis, rib, and other sites^[@R11],[@R24]--[@R26],[@R28],[@R49],[@R51],[@R154]^ and in some cases spinal cord compression.^[@R56],[@R63],[@R73],[@R132]^

### Dimension 4. Neurobiological, Psychosocial, and Functional Consequences of CIBP {#S7}

The consequences of CIBP can be serious because they affect biological, psychological, and functional aspects of the patient's life.^[@R38],[@R73],[@R137]^ Although some pathologic fractures produce limited pain, primary or metastatic bone lesions affecting the femur, pelvis, or spine are likely to cause significant pain during standing or ambulation, resulting in reduced mobility.^[@R63]^ Reduced quality of life and diminished activities of daily living are associated with CIBP.^[@R41],[@R44],[@R48],[@R49],[@R91],[@R118],[@R132],[@R134],[@R160]^ Functional impairment is strongly associated with evoked or breakthrough pain.^[@R92],[@R113]^ Fatigue is frequently reported in patients with metastatic bone disease and resultant pain.^[@R133]^

Depression is common in people with painful bone metastases and has been reported to be significantly associated with impaired quality of life.^[@R134]^ Additionally, the meaning of pain as a sign of advancing disease in individuals with CIBP has been shown to be correlated with increased pain intensity.^[@R134]^ Anxiety in men with advanced prostate cancer is associated with increased pain intensity and number of metastatic bone lesions.^[@R86]^ These studies reveal that the consequences of CIBP are not unlike those seen in chronic noncancer pain syndromes, including impaired function, mood, and quality of life.^[@R60],[@R155]^

### Dimension 5. Putative Neurobiological and Psychosocial Mechanisms, Risk Factors, and Protective Factors for CIBP {#S8}

CIBP is a mixed mechanism condition that includes elements of acute nociceptive pain, inflammatory pain, and neuropathic pain.^[@R58],[@R61],[@R70],[@R103],[@R125],[@R132]^ Distinctive peripheral modifications to bone and nervous tissues occur as well as neurobiological changes at the level of the spinal cord.^[@R61],[@R70]^

Acute nociceptive pain occurs because of localized bone destruction, which leads to loss of structural integrity and a decrease in pH. Cancer cells do not destroy bone directly, but rather they express the receptor activator of nuclear factor κB ligand (RANKL), which binds to its receptor, RANK. Activation of the RANKL/RANK pathway stimulates the production of bone-destroying osteoclasts.^[@R103]^ Osteoclasts resorb bone by forming a highly acidic environment between the osteoclast and the bone. This stimulates the TRPV1 or ASIC3 channels expressed by a significant population of nociceptors that ultimately leads to the perception of incident pain with movement and weight-bearing activities.^[@R61]^

Inflammatory pain develops when peripheral nerve endings in bone marrow and bone matrix are sensitized by localized inflammatory mediators stimulated by the cancer cells or their associated stromal cells. Locally released factors include bradykinin, endothelins, interleukin-6, granulocyte-macrophage colony-stimulating factor, nerve growth factor, proteases, and tumor necrosis factor −α.^[@R103]^ This change is generally associated with steady background pain.^[@R61]^

Neuropathic pain results from compression, distension, increase in sprouting, or denervation of nerve endings and/or axonal structures caused by expansion of the tumor. These changes lead to spontaneous pain and associated altered sensations.^[@R61]^

Nociceptive and neuropathic mechanisms work in concert to produce a complex mixture of ongoing acute, inflammatory, and neuropathic processes. These processes lead to a hyperexcitable state within the spinal cord, which itself is associated with amplification and modification of noxious and non-noxious peripheral stimuli.^[@R61],[@R70],[@R156]^

Interventions to protect against CIBP have been developed on the basis of current understanding of the underlying neurobiology. Bisphosphonates bind to bone, interfering with osteoclast function, later resulting in osteoclast apoptosis.^[@R103]^ Osteoprotegerin or denosumab, therapies that interfere with RANKL binding to RANK deplete activated osteoclasts, reduce signs of bone resorption, and diminish bone cancer pain.^[@R146]^ This is a rapidly evolving area of research and numerous studies are underway to examine compounds that might block CIBP.^[@R146]^ Regarding putative psychosocial mechanisms associated with CIBP or other risk factors, little is currently understood and additional research is warranted.

Chemotherapy-Induced Peripheral Neuropathy {#S9}
------------------------------------------

CIPN is a serious treatment-induced toxicity that can limit function, impair quality of life, and in some cases, diminish the potential for cure when chemotherapy doses need to be reduced.^[@R9]^ This condition is increasing in prevalence as greater numbers of neurotoxic agents are introduced and as patients live longer with the consequences of neuropathy. In a recent systematic review of 31 studies with data from 4,179 patients, CIPN prevalence was 68.1% in the first month after chemotherapy, 60.0% at 3 months, and 30.0% at 6 months or later.^[@R141]^

### Dimension 1. Core Diagnostic Criteria of CIPN {#S10}

CIPN occurs in oncology patients when treatment involves a neurotoxic agent. A temporal relationship exists between the onset of symptoms and the starting, stopping, and duration of therapy.^[@R34],[@R37],[@R46],[@R62],[@R78],[@R148]^ Peripheral sensory and motor nerve damage or dysfunction are the putative mechanisms for CIPN.^[@R36],[@R37],[@R62],[@R101],[@R121],[@R148],[@R151],[@R162]^

CIPN poses a significant challenge for the patient and clinician in terms of diagnosis, management, and associated reductions in function and quality of life, particularly in patients with coexisting conditions or disorders that involve the peripheral nervous system (eg, diabetes, HIV).^[@R2],[@R33],[@R68],[@R78],[@R80],[@R81],[@R104],[@R120],[@R121],[@R148],[@R151]^ [Table 2](#T2){ref-type="table"} shows the core diagnostic criteria for CIPN.

### Dimension 2. Common Features of CIPN {#S11}

The cardinal feature of dose-limiting CIPN is a gradually progressive distal symmetrical sensory neuropathy (stocking/glove distribution), which may be associated with diminished motor function. However, more often than not motor symptoms are absent until later stages of CIPN.^[@R3],[@R13],[@R36],[@R37],[@R62],[@R78],[@R80],[@R101],[@R121],[@R148],[@R151],[@R162]^ Neuropathy in the feet without involvement in the hands is common. In addition to descriptors such as "tingling" or "burning," patients often describe these sensory abnormalities with terms such as "discomfort" or "unpleasant." Cramping, more common in the lower limbs, may be reported.^[@R151]^

Clinical examination reveals sensory loss to one or more sensory modalities and/or evoked pain in a stocking and glove distribution. These findings include hypoesthesia (a bilateral increase in detection thresholds to tactile, vibration, or non-noxious warm or cool stimuli),^[@R53],[@R57],[@R78]^ or hypoalgesia (a bilateral increase in pain detection thresholds to blunt pressure or pinprick stimuli),^[@R53],[@R57],[@R78]^ or hyperalgesia (a bilateral decrease in pain detection threshold to noxious heat or cold stimuli).^[@R18],[@R53]^ The anatomic distribution of these physical examination findings may not correspond exactly to the sensory symptoms.^[@R2],[@R30],[@R46],[@R53],[@R78],[@R80],[@R109],[@R115],[@R120],[@R148],[@R152],[@R158],[@R162]^

Signs and symptoms of CIPN, including pain, commonly begin in the lower extremities followed by the upper extremities and progress proximally.^[@R78]^ However, not all go on to experience neuropathy in the upper extremities. The temporal features of CIPN are rapid onset (hours or days) of sensory abnormalities after initiation of neurotoxic chemotherapy.^[@R78],[@R101]^ In most cases, the onset of CIPN symptoms and signs is progressive; beginning with mild paresthesias in the lower extremities, becoming progressively more intense, and advancing proximally with cumulative dose exposure.^[@R78],[@R101]^

Some patients may experience a reduction in the intensity of symptoms between treatment cycles---sometimes referred to as a waxing and waning effect.^[@R122]^ In some cases, symptoms and signs of CIPN may continue or worsen after treatment hasended, a phenomenon known as 'coasting.'^[@R37],[@R78],[@R101]^ Increasing evidence suggests that pre-existing sensory deficits (clinical or subclinical neuropathy) are associated with the onset of more extensive and severe CIPN symptoms and signs.^[@R18],[@R53]^ The prevalence of autonomic changes associated with CIPN is poorly understood, but can include serious complications such as falls related to orthostatic hypotension.^[@R1]^

Agents most likely to result in CIPN include platinum-based drugs (eg, cisplatin, carboplatin, and oxaliplatin), vinca alkaloids (eg, vincristine, vinblastine), taxanes (eg, paclitaxel, docetaxel), bortezomib, thalidomide, lenalidomide, eribulin, and ixabepilone. The frequency and severity of CIPN is generally related to the specific drug, dose, schedule (eg, more prevalent with weekly vs every 3 weeks dosing of paclitaxel), speed of administration, and duration of therapy.^[@R111]^ In the case of bortezomib, route of delivery affected the prevalence of CIPN. Peripheral neuropathy of any grade was significantly less common with subcutaneous bortezomib administration compared with intravenous delivery.^[@R114]^

Sensations described by patients vary with the administered chemotherapeutic agent. In a recent prospective study that compared the experience of patients receiving docetaxel versus oxaliplatin, tingling was the most common symptom experienced by both groups, yet pain and discomfort associated with cold was uniquely reported by those who received oxaliplatin.^[@R157]^

Motor weakness, with a similar peripheral distribution to sensory alterations, can occur in CIPN, but overall is observed less frequently than sensory abnormalities.^[@R62],[@R101],[@R141]^ However, patients frequently show a decrease in mechanosensory function, measured using a timed pegboard test or the time taken to button a shirt.^[@R16],[@R17],[@R128]^ Importantly, impaired proprioception is reported by many patients with CIPN, described as feeling unbalanced, particularly in the absence of visual cues when walking or standing (eg, in dark settings, when closing one's eyes in the shower).^[@R78],[@R116]^ Clinical examination may reveal a positive Romberg sign and generalized ataxia in more severe cases.^[@R124]^ Symmetrical loss of deep tendon reflexes (Achilles or bra-chioradialis) is a sign of more advanced CIPN.^[@R78]^

### Dimension 3. Common Medical Comorbidities of CIPN {#S12}

People at greatest risk for CIPN are believed to include those with comorbid conditions known to contribute to neuropathy, including diabetes, obesity, and HIV.^[@R81],[@R128],[@R141]^ Pharmacogenetic profiling of genetic polymorphisms has been conducted to identify susceptibility to CIPN on the basis of genetic polymorphisms. For example, polymorphisms in the *CYP2C8* and *CYP3A5* genes that encode for paclitaxel-metabolizing enzymes were found to be associated with CIPN.^[@R31],[@R82]^ Although pharmacogenetic profiling may one day identify patients at greater risk for severe CIPN, the data so far are insufficient to draw any definitive conclusions.

### Dimension 4. Neurobiological, Psychosocial, and Functional Consequences of CIPN {#S13}

Terminal axonal degeneration and axonal microtubule disruption are the most common pathophysiologic consequences observed in CIPN.^[@R78]^ Psychosocial consequences of CIPN include depression, anxiety, impaired sleep, and other mood changes.^[@R69],[@R83],[@R151],[@R157]^ The functional outcomes of CIPN range from mild symptoms that do not interfere with activities of daily living to moderate and severe dose-limiting sensory and motor alterations that interfere with activities of daily living.^[@R32],[@R34]--[@R37],[@R131]^ The need to limit doses of chemotherapy because of CIPN can lead to shortened survival. In the most severe cases sensory and motor alterations are disabling, resulting in paralysis, complete loss of function, or both.^[@R101],[@R104],[@R147]^

### Dimension 5. Putative Neurobiological and Psychosocial Mechanisms, Risk Factors, and Protective Factors for CIPN {#S14}

The underlying pathophysiologic mechanism(s) that lead to the development of CIPN are not completely understood. Nevertheless, the similarity in the pattern and spectrum of clinical symptoms and signs of CIPN caused by different chemotherapeutic agents is apparent. Common underlying mechanisms purported to be involved in the development of CIPN are^[@R5],[@R12],[@R23],[@R62],[@R77],[@R119],[@R122],[@R152],[@R161],[@R162]^: Disruption of axoplasmic microtubule-mediated transport causing distal axonopathy, a known cellular effect of many chemotherapy agents;Distal axonal degeneration;Direct damage to sensory nerve cell bodies of the dorsal root ganglia;Mitochondrial dysfunction;Activation of protein kinases and extracellular kinases (associated with cisplatin- induced CIPN);Oxaliplatin is associated with actual nerve cell death and decreased epidermal nerve fiber density with each cycle, as well as decreased conduction velocity and amplitude;Alteration of gene expression thought to be involved in pain mediation in spinal cord dorsal horn (associated with vincristine exposure);Decrease in the density of gray matter after 1 month in women with breast cancer experiencing CIPN;Central sensitization as a consequence of long-term peripheral nerve injury.

A recent systematic review explored risk factors for CIPN and reported the following elements: baseline neuropathy, smoking, abnormal creatinine clearance, and distinct sensory changes during chemotherapy treatment, including cold allodynia and cold hyperalgesia.^[@R141]^ Sensory changes during chemotherapy treatment, including increased pain and neuronal hyperexcitability, are also predictors of CIPN.^[@R141]^ A prospective study of patients receiving oxaliplatin and followed for 1 year reported that patients with elevated heat detection thresholds (higher temperature levels were needed to perceive heat) before receiving chemotherapy were more likely to experience intense CIPN.^[@R128]^

Few protective factors for CIPN have been identified. A recent investigation used large Medicare claims data and reported that a history of autoimmune disease was associated with reduced risk of CIPN.^[@R81]^ Regarding prevention of CIPN, a recent clinical practice guideline from the American Society of Clinical Oncology reviewed existing evidence. After extensive analysis, the authors were unable to recommend any agents to prevent this syndrome because of the lack of high-quality evidence.^[@R80]^

Pancreatic Cancer Pain {#S15}
----------------------

The estimated incidence of pancreatic cancer for 2016 is more than 53,000 in the United States, with approximately 42,000 dying from this disease.^[@R144]^ Risk factors for pancreatic cancer include family history, obesity, smoking, and chronic pancreatitis.^[@R89],[@R145],[@R149]^ Upper abdominal pain is a common presenting symptom of pancreatic cancer. The prevalence of pain associated with pancreatic cancer ranges from 72 to 100%.^[@R15]^

### Dimension 1. Core Diagnostic Criteria of PCP {#S16}

PCP occurs in the presence of a diagnosis of pancreatic cancer confirmed by imaging evidence of an epigastric mass and/or biopsy that establishes the diagnosis. [Table 3](#T3){ref-type="table"} shows the core diagnostic criteria.

### Dimension 2. Common Features of PCP {#S17}

The cardinal features of PCP are upper abdominal pain with frequent extension to the back, either to the low back or the region between the scapulae spreading laterally, and unexplained weight loss.^[@R143]^ Less frequently PCP is diffuse within the abdomen or referred to the lower abdominal quadrants.^[@R27],[@R90]^ The pain is often described as dull, aching, gnawing, or spasmodic^[@R27],[@R143]^ and the intensity can fluctuate throughout the day with position (eg, exacerbated by supine positioning) and food ingestion.^[@R143]^ Pain intensity usually increases with disease severity. However, because this cancer is often diagnosed late, 20 to 30% of patients report moderate to severe pain at diagnosis.^[@R27]^ The back pain associated with PCP may be worse when the patient is supine and eased by sitting forward.^[@R27],[@R90],[@R143]^

### Dimension 3. Common Medical Comorbidities of PCP {#S18}

Jaundice and dark urine can be a presenting symptom in cancers of the pancreatic head.^[@R143]^ Unexplained weight loss, anorexia, diabetes, and other sequelae of pancreatic cancer or its treatment are common.^[@R15],[@R90],[@R143]^ To date, few medical comorbidities of PCP have been identified.

### Dimension 4. Neurobiological, Psychosocial, and Functional Consequences of PCP {#S19}

Because pancreatic cancer is highly associated with pain, it is difficult to discern whether other symptoms are related to the cancer or pain. Several studies have documented a very high prevalence of depressed mood in patients with pancreatic cancer, higher than other cancers with similar prognoses.^[@R8],[@R27],[@R45]^ Symptom burden in general is high in this population, notably including disturbed sleep and fatigue^[@R90]^ as well as nausea and vomiting associated with obstruction or delayed gastric emptying.^[@R15]^

### Dimension 5. Putative Neurobiological and Psychosocial Mechanisms, Risk Factors, and Protective Factors for PCP {#S20}

Pain occurs in 90% of patients with cancer of the head of the pancreas and is much less common in cancer of pancreatic body or tail.^[@R27],[@R64],[@R143]^ Back pain often indicates that retroperitoneal or celiac plexus infiltration has occurred.^[@R143]^ Putative mechanisms include compression or infiltration (perineural invasion) of splanchnic nerves in the celiac plexus by direct local tu-mor expansion,^[@R8],[@R19],[@R117],[@R143]^ as well as compression of surrounding tissues and organs. Celiac plexus block has been reported to be effective in relieving PCP.^[@R4],[@R107],[@R135]^ It is unclear if relief signifies extension of tumor into the plexus, or interruption of visceral afferent neurons that are also found in the plexus. No other risk factors or protective factors for PCP could be identified.

Discussion {#S21}
==========

Cancer-related pain remains a complex, multidimensional phenomenon. The exercise of developing a standardized, rigorous, valid taxonomy for just 3 common cancer pain syndromes revealed the limitations in our existing nomenclature. Current studies attempting to characterize and establish prevalence rates for specific cancer pain syndromes are hampered by the absence of explicit definitions. A clear example is the large, prospective study by Ventzel and colleagues comparing neuropathy characteristics in patients receiving oxaliplatin versus docetaxel.^[@R157]^ Although the prevalence of pain in the hands and feet was approximately equal between the 2 groups, on further analysis, a significant percentage of those treated with docetaxel reported less burning and numbness, suggesting the pain was not consistent with CIPN. The investigators postulated this difference may be related to the use of adjuvant endocrine therapies, such as the aromatase inhibitors, often prescribed for those who have received docetaxel. These endocrine therapies are known to cause arthralgias, myalgias, and carpal tunnel syndrome.^[@R110],[@R142]^ The investigators used a variety of questionnaires to determine these differences, yet not all clinicians or researchers will be able to use such an extensive battery of measures. It is our hope that the core diagnostic criteria will help future investigators to not only better characterize cancer pain syndromes, as was done in this study, but to differentiate them from related phenomenon to avoid inaccurate interpretations.^[@R100]^

The consequences of cancer pain can be significant, including deleterious effects on function, mood, sleep, fatigue, and ultimately, quality of life.^[@R60],[@R155]^ Additionally, increased intensity of cancer pain is associated with heightened suffering in those at end of life.^[@R159]^ Finally, studies support the association between pain and reduced survival, demanding more urgent attention to this symptom.^[@R76],[@R129]^ More research is warranted to discern the neurobiological, psychological, and functional consequences of each of these and other cancer pain syndromes.

Another area that demands additional study is the determination of the mechanisms of cancer pain. Although important work has begun in the area of CIBP,^[@R39],[@R102],[@R103],[@R105]^ CIPN,^[@R66],[@R74],[@R97],[@R98]^ and PCP,^[@R55],[@R93]^ additional research is needed to elucidate the neurobiological factors responsible for cancer pain. An exciting line of investigation is the interactions among the cancer microenvironment, the primary afferent nociceptor, and the immune system.^[@R138],[@R139]^

An additional area of clarification relates to risk factors and protective determinants for cancer pain. Early research exploring cancer pain focused on clinical or biological factors, such as cancer diagnosis, stage of disease, or treatment. In recent important work, Miaskowski and colleagues reported that cancer patients with the highest symptom burden were significantly younger, more likely to be female and nonwhite, had lower levels of social support, lower socioeconomic status, poorer functional status, and a higher level of comorbidity.^[@R108]^ In a large study of people with breast cancer, colorectal cancer, or prostate cancer, Lewis et al reported that factors associated with more severe CIPN included colon versus other cancers, the duration and type of therapy, poor socioeconomic status, and black race.^[@R96]^ Factors influencing cancer pain must be expanded in future studies, including psychosocial factors^[@R60]^ and overlapping chronic pain conditions and comorbidities.^[@R100]^ Additionally, identification of genetic polymorphisms might allow for the identification of those at risk for these painful syndromes, as well as direct prevention and treatment innovations.

Finally, an emerging area of research that requires further investigation is the development of phenotypic profiles of cancer pain syndromes on the basis of symptoms and clinical signs. Recent studies in noncancer chronic pain syndromes (such as diabetic peripheral neuropathy) suggest that stratification of patients into homogeneous groups on the basis of symptom profiles may be advantageous for analgesic drug trials and ultimately lead to a more targeted approach to cancer pain management.^[@R67],[@R150]^

This proposed taxonomy presents early work in developing a classification system for cancer-related pain conditions. Current classification systems focusing on duration (acute vs chronic) or presumed etiology (related to the cancer, related to treatment, or unrelated) do not provide the specificity needed to clearly define distinct cancer pain syndromes. There were numerous challenges in the development process, notably limitations in existing research related to cancer pain. Studies are often hampered by a wide array of weaknesses, including heterogeneous populations, small sample sizes, dissimilar assessment tools and techniques, and inadequate duration of investigations. Although the working group strove to identify diagnostic criteria that were absolutely necessary to describe each painful syndrome, when these criteria are applied more broadly, controversy will arise and modification will likely be indicated. Future work will now be required to validate this proposed taxonomy in populations of people with cancer and determine the feasibility of its use in clinical as well as research settings. Investigators studying these 3 syndromes should incorporate the core diagnostic criteria when using research methods. Clinicians may find the use of the criteria of benefit when considering the differential diagnosis of complex cancer pain syndromes. This current undertaking classified just 3 syndromes; much additional work is needed to characterize the many other painful syndromes that occur in individuals diagnosed with cancer.

Conclusions {#S22}
===========

Three cancer pain syndromes, 2 related to cancer, and 1 related to a common cancer treatment, were classified using the AAPT multidimensional chronic pain taxonomy. Future work will show the validity and reliability of these proposed diagnostic criteria.^[@R21]^ As our understanding of these cancer pain conditions matures, it is expected that the taxonomy will expand and evolve. It is the hope of this working group that classification of these cancer pain syndromes will ultimately strengthen clinical, scientific, and educational efforts around cancer pain. Transforming our understanding of cancer pain is urgently needed to improve its management as well as improve patients' relief and survivors' quality of life.
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###### 

Dimension 1: Core Diagnostic Criteria for Cancer-Induced Bone Pain

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Criteria History of primary or metastatic bone cancer diagnosed using imaging and physical examinationPresence of continuous, background pain (usually described as annoying, dull, gnawing, aching, and/or nagging) in 1 or more locations generally consistent with known distribution of bone lesions^[@R40],[@R41],[@R43],[@R48],[@R50],[@R61],[@R92],[@R133]^Presence of evoked or spontaneous pain (often described as electric or shock-like) in 1 or more locations generally consistent with known distribution of bone lesions, associated with weight-bearing or movement or can occur spontaneously^[@R40],[@R41],[@R43],[@R49],[@R50],[@R61],[@R85],[@R92],[@R133]^Clinical examination over the site of pain reveals: Hyperalgesia to blunt, non-noxious pressure, or pin-prick stimuli, orHypoesthesia to non-noxious thermal stimuli, orHypoesthesia to light touch stimuli^[@R140]^
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Dimension 1: Core Diagnostic Criteria for Chemotherapy-Induced Peripheral Neuropathy

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Criteria Onset of pain after exposure to a chemotherapeutic agent known to be neurotoxicPresence of painful symptoms in a symmetrical stocking and glove distribution beginning in lower extremities which may progress to the upper extremities, although finding in the feet and not in the hands is commonPainful symptoms are accompanied by nonpainful symptoms (eg, "pins and needles" or numbness) in a similar distributionClinical examination reveals sensory loss to 1 or more sensory modalities and/or evoked pain in a stocking and glove distribution, as reflected in at least 1 of the following: Hypoesthesia: bilateral increase in detection thresholds to tactile, vibration, or non-noxious warm or cool stimuli, orHypoalgesia: bilateral increase in pain detection thresholds to blunt pressure or pinprick stimuli, orHyperalgesia: bilateral decrease in pain detection threshold to noxious heat or cold stimuliMagnitude of the sensory abnormalities is disproportionately greater than the magnitude of any motor abnormalities in the affected region (except in the case of neuropathy after vinca alkaloids)No other condition (eg, polyneuropathy of other origin) could plausibly account for painful symptoms
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Dimension 1: Core Diagnostic Criteria for Pancreatic Cancer Pain

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Criteria History of pancreatic cancer diagnosed using imaging, physical examination, and in some cases biopsy and laboratory analysis of blood or tissues for tumor markersPresence of pain in upper abdominal region (typically referred to the epigastric region or upper abdominal quadrants) spreading posteriorly and/or radiating to the backOn clinical examination, the patient displays tenderness on upper abdominal palpationNo other condition (eg, constipation) could plausibly account for persisting pain in the upper abdomen
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### Perspective

The ACTTION-APS chronic cancer pain taxonomy provides an evidence-based classification for 3 prevalent syndromes, namely malignant bone pain, pancreatic cancer pain, and chemotherapy-induced peripheral neuropathy. This taxonomy provides consistent diagnostic criteria, common features, comorbidities, consequences, and putative mechanisms for these potentially serious cancer pain conditions that can be extended and applied with other cancer-related pain syndromes.
